Dramatic response to Evinacumab in a North Indian girl with homozygous familial hypercholesterolemia
Journal of Pediatric Endocrinology and Metabolism · 2025
DOI: 10.1515/jpem-2024-0506 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Pediatric Endocrinology and Metabolism, 2025. Verfasst von Sonali Arora und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Endocrinology and Diabetes Unit, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Homozygous Familial Hypercholesterolemia, Antibodies, Monoclonal, Anticholesteremic Agents, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Objectives
Homozygous familial hypercholesterolemia (HoFH) is a rare inherited disorder of lipoprotein metabolism associated with significant morbidity and early mortality. The conventional management with lipid-lowering drugs and lipoprotein apheresis is unable to consistently achieve guidelines recommended low-density lipoprotein cholesterol (LDL-C). We aim to describe the efficacy of Evinacumab, a recently approved monoclonal antibody, in lowering LDL-C in an Indian girl with HoFH. Case presentation A 16-year-old girl was diagnosed with HoFH at age two years after the appearance of cutaneous and tendo-calcaneus xanthomas. Genetic testing revealed a pathogenic homozygous deletion in the LDL receptor (LDLR) gene. Despite lifestyle measures, a low-fat diet, and maximum doses of atorvastatin and ezetimibe, her average LDL-C level remained 320.3 mg/dL over the past decade. Her caregivers did not accept LDL-apheresis. She also did not respond to Evolocumab therapy. The patient developed progressive calcific aortic stenosis and concentric left ventricular hypertrophy, necessitating aortic valve replacement surgery at age 16 years. The recent addition of Evinacumab to her lipid-lowering drug regimen, resulted in a significant LDL-C reduction of 76.16 %, bringing levels down to 82 mg/dL. These levels were sustained over the last four months.
Conclusions
Evinacumab offers a promising option for managing high-risk and difficult-to-treat HoFH patients. This is the first Indian child receiving Evinacumab for HoFH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Endocrinology and Diabetes Unit, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Cardiovascular and Thoracic Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Cardiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
ORCID-Profile: Sayan Banerjee, Devi Dayal
Zitieren
APA
Arora, S., Banerjee, S., George, A., Bala, A., Thingnam, S. K. S., Rohit, M. K., & Dayal, D. (2025). Dramatic response to Evinacumab in a North Indian girl with homozygous familial hypercholesterolemia. Journal of Pediatric Endocrinology and Metabolism. https://doi.org/10.1515/jpem-2024-0506
Vancouver
Arora S, Banerjee S, George A, Bala A, Thingnam SKS, Rohit MK, et al. Dramatic response to Evinacumab in a North Indian girl with homozygous familial hypercholesterolemia. Journal of Pediatric Endocrinology and Metabolism. 2025. doi:10.1515/jpem-2024-0506
BibTeX
@article{Arora2025,
author = {Arora, Sonali and Banerjee, Sayan and George, Arun and Bala, Anju and Thingnam, Shyam Kumar Singh and Rohit, Manoj Kumar and Dayal, Devi},
title = {Dramatic response to Evinacumab in a North Indian girl with homozygous familial hypercholesterolemia},
journal = {Journal of Pediatric Endocrinology and Metabolism},
year = {2025},
doi = {10.1515/jpem-2024-0506}
}
EUVIMED